Skip to main content

Multiple Myeloma

Multiple Myeloma, Oncology
Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma
Phoebe Starr
Phoebe Starr
Read More
Breast Cancer, FDA Approvals, In the News, Multiple Myeloma, Pediatric Cancer, Oncology
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Read More
FDA Approvals, Multiple Myeloma, In the News, Oncology
FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma
Read More
Multiple Myeloma, Oncology
Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma
Chase Doyle
Chase Doyle
Read More
Multiple Myeloma, Oncology
Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma
Chase Doyle
Read More
Multiple Myeloma, Oncology
CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
ASCO 2017: Multiple Myeloma Highlights
Read More
Multiple Myeloma, Oncology
American Society of Hematology 2016: Multiple Myeloma Highlights
Read More
Multiple Myeloma, Oncology
HIV Drug Shows Promise in Refractory Multiple Myeloma
Charles Bankhead
Read More
Page 2 of 6
Results 11 - 20 of 53